{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T10:41:47Z","timestamp":1787222507542,"version":"build-2736575974"},"reference-count":59,"publisher":"Spandidos Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.3892\/ijmm.2013.1444","type":"journal-article","created":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T06:21:37Z","timestamp":1373955697000},"page":"763-767","source":"Crossref","is-referenced-by-count":135,"title":["Therapeutics targeting angiogenesis: Genetics and epigenetics, extracellular miRNAs and signaling networks (Review)"],"prefix":"10.3892","volume":"32","author":[{"given":"MASARU","family":"KATOH","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2013,7,16]]},"reference":[{"key":"key20180107225837_b1-ijmm-32-04-0763","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/nature04478","article-title":"Angiogenesis in life, disease and medicine","volume":"438","author":"Carmeliet","year":"2005","journal-title":"Nature"},{"key":"key20180107225837_b2-ijmm-32-04-0763","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nature04483","article-title":"Angiogenesis as a therapeutic target","volume":"438","author":"Ferrara","year":"2005","journal-title":"Nature"},{"key":"key20180107225837_b3-ijmm-32-04-0763","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrd2115","article-title":"Angiogenesis: an organizing principle for drug discovery?","volume":"6","author":"Folkman","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"key20180107225837_b4-ijmm-32-04-0763","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature10144","article-title":"Molecular mechanisms and clinical applications of angiogenesis","volume":"473","author":"Carmeliet","year":"2011","journal-title":"Nature"},{"key":"key20180107225837_b5-ijmm-32-04-0763","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1161\/ATVBAHA.107.161521","article-title":"Endothelial-mural cell signaling in vascular development and angiogenesis","volume":"29","author":"Gaengel","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"key20180107225837_b6-ijmm-32-04-0763","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/nature04479","article-title":"Endothelial cells and VEGF in vascular development","volume":"438","author":"Coultas","year":"2005","journal-title":"Nature"},{"key":"key20180107225837_b7-ijmm-32-04-0763","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/nrm1911","article-title":"VEGF receptor signalling-in control of vascular function","volume":"7","author":"Olsson","year":"2006","journal-title":"Nat Rev Mol Cell Biol"},{"key":"key20180107225837_b8-ijmm-32-04-0763","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.cytogfr.2005.01.004","article-title":"Fibroblast growth factor\/fibroblast growth factor receptor system in angiogenesis","volume":"16","author":"Presta","year":"2005","journal-title":"Cytokine Growth Factor Rev"},{"key":"key20180107225837_b9-ijmm-32-04-0763","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.canlet.2012.08.018","article-title":"Angiopoietins in angiogenesis","volume":"328","author":"Fagiani","year":"2013","journal-title":"Cancer Lett"},{"key":"key20180107225837_b10-ijmm-32-04-0763","doi-asserted-by":"crossref","first-page":"569","DOI":"10.2217\/fon.11.20","article-title":"Notch regulation of tumor angiogenesis","volume":"7","author":"Bridges","year":"2011","journal-title":"Future Oncol"},{"key":"key20180107225837_b11-ijmm-32-04-0763","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1158\/1078-0432.CCR-06-2316","article-title":"WNT signaling pathway and stem cell signaling network","volume":"13","author":"Katoh","year":"2007","journal-title":"Clin Cancer Res"},{"key":"key20180107225837_b12-ijmm-32-04-0763","first-page":"271","article-title":"Hedgehog signaling, epithelial-to-mesenchymal transition and miRNA (Review)","volume":"22","author":"Katoh","year":"2008","journal-title":"Int J Mol Med"},{"key":"key20180107225837_b13-ijmm-32-04-0763","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nature12296","article-title":"The linear ubiquitin-specific deubiquitinase gumby regulates angiogenesis","volume":"498","author":"Rivkin","year":"2013","journal-title":"Nature"},{"key":"key20180107225837_b14-ijmm-32-04-0763","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/nm.2719","article-title":"Neighborhood watch orchestrates liver regeneration","volume":"18","author":"Diehl","year":"2012","journal-title":"Nat Med"},{"key":"key20180107225837_b15-ijmm-32-04-0763","article-title":"FGF receptors: cancer biology and therapeutics","author":"Katoh","year":"2013","journal-title":"Med Res Rev"},{"key":"key20180107225837_b16-ijmm-32-04-0763","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/nrc2397","article-title":"Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response","volume":"8","author":"Dewhirst","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"key20180107225837_b17-ijmm-32-04-0763","first-page":"272","article-title":"The biological kinship of hypoxia with CSC and EMT and their relationship with deregulated expression of miRNAs and tumor aggressiveness","volume":"1826","author":"Bao","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"key20180107225837_b18-ijmm-32-04-0763","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.bbrc.2005.05.132","article-title":"Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy","volume":"333","author":"Ferrara","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"key20180107225837_b19-ijmm-32-04-0763","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell-lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N Engl J Med"},{"key":"key20180107225837_b20-ijmm-32-04-0763","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ctrv.2011.06.004","article-title":"Targeting angiogenesis in ovarian cancer","volume":"38","author":"Schmitt","year":"2012","journal-title":"Cancer Treat Rev"},{"key":"key20180107225837_b21-ijmm-32-04-0763","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/bjc.2012.541","article-title":"Targeted anti-vascular therapies for ovarian cancer: current evidence","volume":"108","author":"Hall","year":"2013","journal-title":"Br J Cancer"},{"key":"key20180107225837_b22-ijmm-32-04-0763","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1200\/JCO.2006.06.3602","article-title":"Sunitinib: from rational design to clinical efficacy","volume":"25","author":"Chow","year":"2007","journal-title":"J Clin Oncol"},{"key":"key20180107225837_b23-ijmm-32-04-0763","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1158\/1535-7163.MCT-08-0013","article-title":"Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling","volume":"7","author":"Wilhelm","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"key20180107225837_b24-ijmm-32-04-0763","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.canlet.2012.03.008","article-title":"Anti-angiogenesis therapy in cancer: current challenges and future perspectives","volume":"320","author":"Shojaei","year":"2012","journal-title":"Cancer Lett"},{"key":"key20180107225837_b25-ijmm-32-04-0763","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.drudis.2011.08.007","article-title":"Anti-VEGF and beyond: shaping a new generation of anti-angiogenic therapies for cancer","volume":"16","author":"Bertolini","year":"2011","journal-title":"Drug Discov Today"},{"key":"key20180107225837_b26-ijmm-32-04-0763","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1158\/1535-7163.MCT-12-0999","article-title":"Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells","volume":"12","author":"Konecny","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"key20180107225837_b27-ijmm-32-04-0763","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"O\u2019Hare","year":"2009","journal-title":"Cancer Cell"},{"key":"key20180107225837_b28-ijmm-32-04-0763","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1158\/0008-5472.CAN-11-3034","article-title":"AZD4547: An orally bioavailable, potent and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family","volume":"72","author":"Gavine","year":"2012","journal-title":"Cancer Res"},{"key":"key20180107225837_b29-ijmm-32-04-0763","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrclinonc.2009.94","article-title":"Adverse effects of anticancer agents that target the VEGF pathway","volume":"6","author":"Chen","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"key":"key20180107225837_b30-ijmm-32-04-0763","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.preteyeres.2008.05.001","article-title":"Vascular endothelial growth factor in eye disease","volume":"27","author":"Penn","year":"2008","journal-title":"Prog Retin Eye Res"},{"key":"key20180107225837_b31-ijmm-32-04-0763","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1161\/01.CIR.0000093398.16124.29","article-title":"Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication","volume":"108","author":"Rajagopalan","year":"2003","journal-title":"Circulation"},{"key":"key20180107225837_b32-ijmm-32-04-0763","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1089\/hum.2006.17.230","article-title":"Intracoronary delivery of an adenovirus encoding fibroblast growth factor-4 in myocardial ischemia: effect of serum antibodies and previous exposure to adenovirus","volume":"17","author":"Roth","year":"2006","journal-title":"Hum Gene Ther"},{"key":"key20180107225837_b33-ijmm-32-04-0763","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1046\/j.1365-2796.2001.00905.x","article-title":"Effects of intramyocardial injection of phVEGF-A165 as sole therapy in patients with refractory coronary artery disease-12-month follow-up: angiogenic gene therapy","volume":"250","author":"Sarkar","year":"2001","journal-title":"J Intern Med"},{"key":"key20180107225837_b34-ijmm-32-04-0763","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(11)60394-2","article-title":"Effect of fibroblast growth factor NV1FGF on amputation and death: a randomised placebo-controlled trial of gene therapy in critical limb ischaemia","volume":"377","author":"Belch","year":"2011","journal-title":"Lancet"},{"key":"key20180107225837_b35-ijmm-32-04-0763","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s10741-011-9285-8","article-title":"Angiogenic therapy for cardiac repair based on protein delivery systems","volume":"17","author":"Formiga","year":"2012","journal-title":"Heart Fail Rev"},{"key":"key20180107225837_b36-ijmm-32-04-0763","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/j.polymer.2008.01.027","article-title":"Hydrogels in drug delivery: Progress and challenges","volume":"49","author":"Hoare","year":"2008","journal-title":"Polymer"},{"key":"key20180107225837_b37-ijmm-32-04-0763","first-page":"505","article-title":"Multipotent adult progenitor cells sustain function of ischemic limbs in mice","volume":"118","author":"Aranguren","year":"2008","journal-title":"J Clin Invest"},{"key":"key20180107225837_b38-ijmm-32-04-0763","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.cytogfr.2009.10.002","article-title":"Mechanisms involved in the therapeutic properties of mesenchymal stem cells","volume":"20","author":"da Meirelles","year":"2009","journal-title":"Cytokine Growth Factor Rev"},{"key":"key20180107225837_b39-ijmm-32-04-0763","doi-asserted-by":"crossref","first-page":"e39562","DOI":"10.1371\/journal.pone.0039562","article-title":"Comparative angiogenic activities of induced pluripotent stem cells derived from young and old mice","volume":"7","author":"Suzuki","year":"2012","journal-title":"PLoS One"},{"key":"key20180107225837_b40-ijmm-32-04-0763","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1056\/NEJM200007133430201","article-title":"Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland","volume":"343","author":"Lichtenstein","year":"2000","journal-title":"N Engl J Med"},{"key":"key20180107225837_b41-ijmm-32-04-0763","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1038\/414782a","article-title":"Global and societal implications of the diabetes epidemic","volume":"414","author":"Zimmet","year":"2001","journal-title":"Nature"},{"key":"key20180107225837_b42-ijmm-32-04-0763","first-page":"503","article-title":"Polymorphisms in endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension","volume":"92","author":"Eechoute","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"key20180107225837_b43-ijmm-32-04-0763","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/bjc.2012.501","article-title":"VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib","volume":"108","author":"Scartozzi","year":"2013","journal-title":"Br J Cancer"},{"key":"key20180107225837_b44-ijmm-32-04-0763","first-page":"1382","article-title":"Local and genetic determinants of vascular endothelial growth factor expression in advanced proliferative diabetic retinopathy","volume":"14","author":"Petrovi\u010d","year":"2008","journal-title":"Mol Vis"},{"key":"key20180107225837_b45-ijmm-32-04-0763","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1038\/bjc.2013.69","article-title":"Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer","volume":"108","author":"Miles","year":"2013","journal-title":"Br J Cancer"},{"key":"key20180107225837_b46-ijmm-32-04-0763","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/nrc3130","article-title":"A decade of exploring the cancer epigenome-biological and translational implications","volume":"11","author":"Baylin","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"key20180107225837_b47-ijmm-32-04-0763","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/nrcardio.2010.104","article-title":"Epigenetics and cardiovascular disease","volume":"7","author":"Ordov\u00e1s","year":"2010","journal-title":"Nat Rev Cardiol"},{"key":"key20180107225837_b48-ijmm-32-04-0763","first-page":"3573","article-title":"Accelerated age-related CpG island methylation in ulcerative colitis","volume":"61","author":"Issa","year":"2001","journal-title":"Cancer Res"},{"key":"key20180107225837_b49-ijmm-32-04-0763","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0002-9440(10)63511-0","article-title":"Aberrant CpG island hypermethylation of chronic gastritis, in relation to aging, gender, intestinal metaplasia, and chronic inflammation","volume":"163","author":"Kang","year":"2003","journal-title":"Am J Pathol"},{"key":"key20180107225837_b50-ijmm-32-04-0763","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.yexmp.2012.10.018","article-title":"Field cancerization in mammary carcinogenesis - Implications for prevention and treatment of breast cancer","volume":"93","author":"Rivenbark","year":"2012","journal-title":"Exp Mol Pathol"},{"key":"key20180107225837_b51-ijmm-32-04-0763","first-page":"200","article-title":"Serum microRNAs as powerful cancer biomarkers","volume":"1806","author":"Wittmann","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"key20180107225837_b52-ijmm-32-04-0763","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.tips.2007.10.014","article-title":"Targeting microRNA expression to regulate angiogenesis","volume":"29","author":"Kuehbacher","year":"2008","journal-title":"Trends Pharmacol Sci"},{"key":"key20180107225837_b53-ijmm-32-04-0763","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.gde.2009.04.002","article-title":"AngiomiRs - key regulators of angiogenesis","volume":"19","author":"Wang","year":"2009","journal-title":"Curr Opin Genet Dev"},{"key":"key20180107225837_b54-ijmm-32-04-0763","doi-asserted-by":"crossref","first-page":"e30679","DOI":"10.1371\/journal.pone.0030679","article-title":"The majority of microRNAs detectable in serum and saliva is concentrated in exosomes","volume":"7","author":"Gallo","year":"2012","journal-title":"PLoS One"},{"key":"key20180107225837_b55-ijmm-32-04-0763","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.tibs.2012.08.003","article-title":"Extracellular miRNAs: the mystery of their origin and function","volume":"37","author":"Turchinovich","year":"2012","journal-title":"Trends Biochem Sci"},{"key":"key20180107225837_b56-ijmm-32-04-0763","doi-asserted-by":"crossref","first-page":"e48814","DOI":"10.1371\/journal.pone.0048814","article-title":"Differential expression of exosomal microRNAs in prefrontal cortices of schizophrenia and bipolar disorder patients","volume":"8","author":"Banigan","year":"2013","journal-title":"PLoS One"},{"key":"key20180107225837_b57-ijmm-32-04-0763","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/ki.2012.105","article-title":"Microvesicles derived from endothelial progenitor cells protect the kidney from ischemia-reperfusion injury by microRNA-dependent reprogramming of resident renal cells","volume":"82","author":"Cantaluppi","year":"2012","journal-title":"Kidney Int"},{"issue":"Suppl 1","key":"key20180107225837_b58-ijmm-32-04-0763","doi-asserted-by":"crossref","first-page":"S189","DOI":"10.1517\/14712598.2012.680018","article-title":"Exosomal RNA as biomarkers and the therapeutic potential of exosome vectors","volume":"12","author":"L\u00e4sser","year":"2012","journal-title":"Expert Opin Biol Ther"},{"key":"key20180107225837_b59-ijmm-32-04-0763","doi-asserted-by":"crossref","first-page":"e61831","DOI":"10.1371\/journal.pone.0061831","article-title":"Early vessel destabilization mediated by Angiopoietin-2 and subsequent vessel maturation via Angiopoietin-1 induce functional neovasculature after ischemia","volume":"8","author":"Qin","year":"2013","journal-title":"PLoS One"}],"container-title":["International Journal of Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/ijmm.2013.1444\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,18]],"date-time":"2019-07-18T06:41:01Z","timestamp":1563432061000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/ijmm.2013.1444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,16]]},"references-count":59,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2013,7,16]]},"published-print":{"date-parts":[[2013,10]]}},"alternative-id":["10.3892\/ijmm.2013.1444"],"URL":"https:\/\/doi.org\/10.3892\/ijmm.2013.1444","relation":{},"ISSN":["1107-3756","1791-244X"],"issn-type":[{"value":"1107-3756","type":"print"},{"value":"1791-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,16]]}}}